Terms: = Breast cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
24 results:
1. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract] [Full Text] [Related]
2. treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC; Slomovitz B; Coleman RL; Pothuri B
Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
[TBL] [Abstract] [Full Text] [Related]
3. KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.
Wen T; Geng M; Bai E; Wang X; Miao H; Chen Z; Zhou H; Wang J; Shi J; Zhang Y; Lei M; Zhu Y
FEBS Open Bio; 2023 Apr; 13(4):751-762. PubMed ID: 36847599
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract] [Full Text] [Related]
5. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44
Liu C; Zhang Y; Gao J; Zhang Q; Sun L; Ma Q; Qiao X; Li X; Liu J; Bu J; Zhang Z; Han L; Zhao D; Yang Y
Drug Resist Updat; 2023 Jan; 66():100903. PubMed ID: 36463808
[TBL] [Abstract] [Full Text] [Related]
6. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract] [Full Text] [Related]
7. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
8. Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.
Shi Y; Xu S; Li S
Mol Cell Endocrinol; 2022 Apr; 545():111558. PubMed ID: 35033575
[TBL] [Abstract] [Full Text] [Related]
9. De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens.
Weiskittel TM; Ung CY; Correia C; Zhang C; Li H
Genome Res; 2022 Jan; 32(1):124-134. PubMed ID: 34876496
[TBL] [Abstract] [Full Text] [Related]
10. Discovery and biological evaluation of a small-molecule inhibitor of crm1 that suppresses the growth of triple-negative breast cancer cells.
Gao J; Chu P; Liu C; Sun Z; Liu Q; Yang Y
Traffic; 2021 Jul; 22(7):221-229. PubMed ID: 34021516
[TBL] [Abstract] [Full Text] [Related]
11. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Martini S; Figini M; Croce A; Frigerio B; Pennati M; Gianni AM; De Marco C; Daidone MG; Argueta C; Landesman Y; Zaffaroni N; Satta A
Cells; 2020 Oct; 9(10):. PubMed ID: 33023194
[TBL] [Abstract] [Full Text] [Related]
12. Budlein A methylacrylate demonstrates potent activity against triple-negative breast cancer by targeting IκBα kinase and exportin-1.
Wang XZ; Feng Y; Han YF; Bian Y; Liang J; Wen HM; Wu H
Toxicol Appl Pharmacol; 2020 Dec; 408():115263. PubMed ID: 33022283
[TBL] [Abstract] [Full Text] [Related]
13. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway.
Seervi M; Sumi S; Chandrasekharan A; Sharma AK; SanthoshKumar TR
Cell Oncol (Dordr); 2019 Oct; 42(5):645-661. PubMed ID: 31147963
[TBL] [Abstract] [Full Text] [Related]
14. Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through crm1-mediated p62/SQSTM1 accumulation and AMPK activation.
Wang H; Wang F; Wu S; Liu Z; Li T; Mao L; Zhang J; Li C; Liu C; Yang Y
Chem Biol Interact; 2018 Feb; 281():11-23. PubMed ID: 29247643
[TBL] [Abstract] [Full Text] [Related]
15. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
[TBL] [Abstract] [Full Text] [Related]
16. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.
Yu T; Yang G; Hou Y; Tang X; Wu C; Wu XA; Guo L; Zhu Q; Luo H; Du YE; Wen S; Xu L; Yin J; Tu G; Liu M
Oncogene; 2017 Apr; 36(15):2131-2145. PubMed ID: 27721408
[TBL] [Abstract] [Full Text] [Related]
17. xpo1/crm1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract] [Full Text] [Related]
18. Differential splicing alters subcellular localization of the alpha but not beta isoform of the MIER1 transcriptional regulator in breast cancer cells.
Clements JA; Mercer FC; Paterno GD; Gillespie LL
PLoS One; 2012; 7(2):e32499. PubMed ID: 22384264
[TBL] [Abstract] [Full Text] [Related]
19. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis.
Bartholomeusz G; Wu Y; Ali Seyed M; Xia W; Kwong KY; Hortobagyi G; Hung MC
Mol Carcinog; 2006 Feb; 45(2):73-83. PubMed ID: 16302269
[TBL] [Abstract] [Full Text] [Related]
[Next]
